Lupin receives tentative USFDA nod for Dolutegravir & Rilpivirine capsules

Lupin receives tentative USFDA nod for Dolutegravir & Rilpivirine capsules

by admin- Monday, January 16th, 2023 03:41:31 PM

Lupin received tentative approval from the USA Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, to market a regularly occurring equal of Juluca Tablets, 50 mg/25 mg of ViiV Healthcare Company.

News Updates